A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IVIG / i.v. immunoglobulin

[Related PubMed/MEDLINE]
Total Number of Papers: 83
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IVIG  (>> Co-occurring Abbreviation)
Long Form:   i.v. immunoglobulin
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Rare Case of Measles-Associated Hemophagocytic Lymphohistiocytosis in an Infant. HLH
2020 Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody. BBE
2020 DEHP Nanodroplets Leached From Polyvinyl Chloride IV Bags Promote Aggregation of IVIG and Activate Complement in Human Serum. DEHP, PVC
2020 IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP. AEs, ITP, IVMP, PCs
2020 Kawasaki disease: Shedding light on a mysterious diagnosis. ---
2020 Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. CAR T cell, CR, ICU, MDS
2020 Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events. FNAIT
2020 Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. ARR, MOG-IgG, MS
2020 Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products. IgG2, KD
10  2019 Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. BTZ, DSAs, MFI
11  2019 Chronic Inflammatory Demyelinating Polyradiculoneuropathy. CIDP, CSF, IgG4
12  2019 Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States. PIDD, s.c, SCIG
13  2019 Indicators of unresponsiveness after initial i.v. immunoglobulin treatment in acute Kawasaki disease. CRP, KD
14  2019 Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease. KD
15  2019 Sivelestat sodium hydrate treatment for refractory Kawasaki disease. KD, SSH
16  2018 Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital. ---
17  2018 Effect of i.v. immunoglobulin in the first 4 days of illness in Kawasaki disease. KD
18  2018 Immune modulation of i.v. immunoglobulin in women with reproductive failure. RF
19  2018 Infliximab regulates monocytes and regulatory T cells in Kawasaki disease. IFX, IL, KD, TNF
20  2018 Kawasaki disease shock syndrome: Unique and severe subtype of Kawasaki disease. KD, KDSS, TSS
21  2018 Predictive factors of response to IVIG in pediatric immune thrombocytopenic purpura. ITP, TFS
22  2018 [Recent Developments in Myositis Syndromes]. ACR, GC, IIM, sIBM
23  2017 A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). IGNG, PID
24  2017 Antiviral treatment of BK virus viremia after kidney transplantation. BKV, BKVAN
25  2017 High neutrophil:lymphocyte ratio is associated with refractory Kawasaki disease. KD, NLR
26  2017 Immunoglobulin-responsive chikungunya encephalitis: two case reports. ---
27  2017 Low risk of treatment resistance in Down syndrome with Kawasaki disease. CAA, DS, KD
28  2017 Relapsing/remitting type 1 diabetes. CIDP
29  2017 Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease. CAL, CRP, KD, PSL
30  2016 Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant. CsA, KD
31  2016 Comparison between IV immune globulin (IVIG) and anti-D globulin for treatment of immune thrombocytopenia: a randomized open-label study. ITP
32  2016 Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease. CRP, KD
33  2016 Time course of cardiac lesions due to Kawasaki disease in Japan: 22nd nationwide survey (2011-2012). KD
34  2016 Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease. KD
35  2015 Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels. BW, IBW, IgG
36  2015 Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. SJS, TEN
37  2015 Recurrent Kawasaki disease: USA and Japan. CAA, CDC, KD
38  2015 Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. SC, SD, SJS, SJS/TEN, ST, TEN
39  2014 Developing a therapeutic plan for treating MS: evidence for new treatments. MS
40  2014 Effect of meropenem with or without immunoglobulin as second-line therapy for pediatric febrile neutropenia. MEPM
41  2014 Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. MG
42  2014 Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. KD, PDMPs
43  2013 N-type calcium channel antibody-mediated autoimmune encephalitis: An unlikely cause of a common presentation. N-type VGCC
44  2012 Idiopathic thrombocytopenic purpura in childhood: twenty years of experience in a single center. ITP
45  2012 Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. CAL, PE
46  2012 Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjogren's syndrome. SS
47  2011 Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease. CAL, KD, PSL
48  2011 Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia. ITP
49  2010 Guillain-Barre syndrome in southern Chinese children: 32 year experience in Hong Kong. GBS, MFS
50  2010 Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy. PM
51  2009 Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. AAG, PE
52  2008 Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. RRMS
53  2007 How intravenous immunoglobulin is used in clinical practice: audits of two Sydney teaching hospitals. ---
54  2007 IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. MG, QMG
55  2007 Randomized controlled trial of short-term withdrawal of i.v. immunoglobulin therapy for selected children with human immunodeficiency virus infection. HIV, VL
56  2007 Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. 6-MP, BBB, SNRS
57  2007 Treatment of antibody-mediated rejection with high-dose immunoglobulins in ABO-incompatible liver transplant recipient. AMR, LT, TAC
58  2007 Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. ---
59  2006 Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states. ---
60  2005 A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. ON
61  2004 Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. FcgammaR, IL-10, ITP, MCP-1, sCD16, TNF-alpha
62  2003 Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. IV immunoglobulin. ---
63  2003 Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination. CIDP, IFN-beta
64  2003 Prospective, randomized comparison of OM-85 BV and a prophylactic antibiotic in children with recurrent infections and immunoglobulin A and/or G subclass deficiency. BPG, Hib, Ig
65  2001 Recent advances in the management of adult myositis. AZA
66  2001 Recent developments in the management of haemophagocytic lymphohistiocytosis. EBV, HLH, NK
67  2001 Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. ---
68  1999 I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. GBS, IL, TNF
69  1997 Parvovirus [correction of Parovirus] B19-induced red cell aplasia in solid-organ transplant recipients. Two case reports and review of the literature. rHuEPO
70  1997 Sepsis and polyspecific intravenous immunoglobulins. ---
71  1996 Intravenous immunoglobulin as sole therapy for systemic vasculitis. ANCA, MPA, WG
72  1995 A prospective, double-blind, placebo-controlled trial of i.v. immunoglobulin and trimethoprim-sulfamethoxazole in children with recurrent respiratory tract infections. TMS
73  1994 Immune globulin use at a multihospital medical center. ---
74  1994 Intravenous immunoglobulin administration: an evaluation of vital sign monitoring. BMT
75  1993 Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection. HIV
76  1993 Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. ---
77  1992 [Effect of various plasma preparations and i.v. immunoglobulins on the function of lymphocytes and monocytes in vitro]. FFP, FP, HP, MLR, MMA
78  1991 Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials. MOF
79  1991 [Supplemental infection therapy with i.v. immunoglobulins (polyvalent IgG and Pseudomonas IgG)--results of an observational case study with 163 patients]. AP, El, MOF
80  1990 Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients. CMV
81  1988 Clinical safety of intravenous immune globulin and freedom from transmission of viral disease. ITP
82  1988 The treatment of human immunodeficiency virus infected patients with intravenous immunoglobulin. AIDS, HIV
83  1988 Treatment of human immunodeficiency virus antibody positive children with intravenous immunoglobulin. HIV